Wikipedia

User:Laurynm2014/sandbox

Laurynm2014/sandbox
Clinical data
Trade namesBromodol, Impromen
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Pharmacokinetic data
Elimination half-life20-22 hours[1]
Excretion1.37 ml/h/kg[1]
Identifiers
  • 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H23BrFNO2
Molar mass420.315 g/mol g·mol−1
3D model (JSmol)
  • Fc1ccc(cc1)C(=O)CCCN3CCC(O)(c2ccc(Br)cc2)CC3
  • InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2 checkY
  • Key:RKLNONIVDFXQRX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bromperidol (marketed as Bromodol, Impromen) is a drug which is a butyrophenone derivative. It is a potent and long-acting neuroleptic, used as an antipsychotic in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1966. Like other typical antipsychotics, bromperidol is a dopamine D2 receptor antagonist. Bromperidol shares many pharmacokinetic and pharmacodynamic features with haloperidol, another butyrophenone derivative. Both have a much higher affinity for D2 receptors than for serotonin 5-HT2A receptors.

Clinical Trials edit

Treatment edit

Bromperidol has been demonstrated to improve symptoms of schizophrenia including positive symptoms, excitement, anxiety, and depression[2]. However, like most other typical antipsychotics, it does not treat the negative or cognitive symptoms of schizophrenia[2].

Side Effects edit

Clinical trials have shown bromperidol can cause extrapyramidal symptoms, including dystonia[1] [3]. The risk of developing dystonia may be related to age, as younger patients were more likely to develop dystonia in one study[3].

References edit

  1. ^ a b c Lee, Soo-Youn (2006). "Pharmacokinetic parameters of bromperidol in Korean subjects". Human Psychopharmacology. 21 (6): 409–412. doi:10.1002/hup.776. PMID 16915578. S2CID 25430156. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  2. ^ a b Yasui-Furukori, Norio (2002). "Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 26 (1): 53–57. doi:10.1016/S0278-5846(01)00218-4. PMID 11853119. S2CID 29476722. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  3. ^ a b Yasui-Furukori, Norio (2002). "The characteristics of side-effects of bromperidol in schizophrenic patients". Psychiatry and Clinical Neurosciences. 56 (1): 103–106. doi:10.1046/j.1440-1819.2002.00936.x. PMID 11929578. S2CID 33540438. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  • Poldinger W, Bures E, Haage H, Clinical study with bromperidol, a new butyrophenone derivative, Int Pharmacopsychiatry. 1977;12(1):20-4.
  • Dubinsky B, McGuire JL, Niemegeers CJ, Janssen PA, Weintraub HS, McKenzie BE, Bromperidol, a new butyrophenone neuroleptic: a review, Psychopharmacology (Berl). 1982;78(1):1-7.


Category:Organobromides Category:Piperidines Category:Alcohols Category:Butyrophenone antipsychotics Category:Janssen Pharmaceutica Category:Belgian inventions


 

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Laurynm2014/sandbox&oldid=983284972"